Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. (March 2018)

• Record Type: Journal Article
• Authors: Sorbo, Maria C.; Cento, Valeria; Di Maio, Velia C.; Howe, Anita Y.M.; Garcia, Federico; Perno, Carlo F.; Ceccherini-Silberstein, Francesca
• Is Part Of: Drug resistance updates. Volume 37(2018)
• Page Start: 17
• Page End: 39
• Publication Date: 2018-03
• Subjects: Direct acting antiviral agents -- Treatment failure -- Fold-change -- HCV genotypic resistance testing -- HCV sequencing; Drug resistance in cancer cells -- Periodicals; Cancer -- Chemotherapy -- Periodicals; 616.994061
• DOI: 10.1016/j.drup.2018.01.004
• Languages: English
• ISSNs: 1368-7646

Abstract

Abstract: Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or in vitro with reduced susceptibility to DAAs, but no comprehensive RASs list is available. This review thus provides an updated, systematic overview of the role of RASs to currently approved DAAs or in phase II/III of clinical development against HCV-infection, discriminating their impact in different HCV-genotypes and DAAs, providing assistance for a fruitful use of HCV resistance testing in clinical practice.